Clinical Characteristics and Outcomes of 421 Patients With Coronavirus Disease 2019 Treated in a Mobile Cabin Hospital

Abstract

BACKGROUND: In December 2019, a novel coronavirus-associated pneumonia, now known as coronavirus disease 2019 (COVID-19), was first detected in Wuhan, China. To prevent the rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treat patients with mild symptoms, sports stadiums and convention centers were reconstructed into mobile hospitals. RESEARCH QUESTION: It is unknown whether a mobile cabin hospital can provide a safe treatment site for patients with mild COVID-19 symptoms. STUDY DESIGN AND METHODS: This study retrospectively reviewed the medical records of 421 patients with COVID-19 admitted to a mobile cabin hospital in Wuhan from February 9, 2020, to March 5, 2020. Clinical data comprised patient age, sex, clinical presentation, chest imaging, nucleic acid testing, length of hospitalization, and outcomes. RESULTS: Of the patients who were discharged from the cabin hospital, 362 (86.0%) were categorized as recovered; 14.0% developed severe symptoms and were transferred to a designated hospital. The most common presenting symptoms were fever (60.6%) and cough (52.0%); 5.2% exhibited no obvious symptoms. High fever (> 39.0 C) was more common in severe cases than in recovered cases (18.6% vs 6.6%). The distribution of lung lesions was peripheral in 85.0% of patients, multifocal in 69.4%, and bilateral in 68.2%. The most common pattern was ground-glass opacity (67.7%), followed by patchy shadowing (49.2%). The incidence of patchy shadowing was higher in patients with severe disease (66.1%) than in those who recovered (31.8%, P < .0001). The median length of hospitalization was 17 days (interquartile range, 14-19 days), and the median time taken for positive real-time reverse transcriptase polymerase chain reaction results to become negative in recovered patients was 8 days (interquartile range, 6-10 days). INTERPRETATION: Mobile cabin hospitals provide a safe treatment site for patients with mild COVID-19 symptoms and offer an effective isolation area to prevent the spread of severe acute respiratory syndrome coronavirus 2.

Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis

“…Most studies were from China 5 , 9 , 11 , 16 – 38 ( n = 26), followed by United States 39 – 43 ( n = 5), Switzerland 44 , 45 ( n = 2), Japan 8 ( n = 1), Korea 46 ( n = 1), Oman 47 ( n = 1), Qatar 48 ( n = 1), Iran 49 ( n = 1), Denmark 50 ( n = 1), Mexico 51 ( n = 1), and Bulgaria 52 ( n = 1). The sample size of included studies ranged from 41 to 5000 patients.…”

The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis

“…Initial database search identified 6196 studies and 34 additional records through reference and citation searches (Figure 1). Overall, 329 of them with full‐text were reviewed for eligibility, of which 124 studies were included in this analysis 7‐9,14‐134 . The NOS scores ranged between 5 and 8.…”

Impact of cardiovascular and metabolic diseases on the severity of COVID-19: a systematic review and meta-analysis

“…Of the 8,170 patients in the 35 studies included in this meta-analysis, 2,415 patients (29.56%) met the criteria for severe COVID-19. Ten studies did not report the prevalence of CHD [ 9 , 18 , 19 , 22 , 24 , 27 , 31 , 32 , 35 , 37 ], five studies did not report the prevalence of hypertension [ 14 , 20 , 32 , 36 , 39 ] and three studies did not report the prevalence of diabetes [ 24 , 34 , 36 ]. The remaining studies reported the prevalence of CHD, hypertension and diabetes in their respective patient pools.…”